{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:31:36Z","timestamp":1785148296053,"version":"3.55.0"},"reference-count":17,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"unspecified","delay-in-days":190,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Roger was a 60-year-old man living with both HIV and schizophrenia who was admitted to the hospital for treatment of a chronic obstructive pulmonary disease exacerbation. He was referred to the psychiatry consultation-liaison team due to persistent psychotic symptoms that had not responded to multiple antipsychotic trials. Roger\u2019s psychiatric history revealed a diagnosis of schizophrenia in early adulthood, marked by hallucinations and delusions of grandeur. Over the next 4 decades, he cycled through jails, prisons, shelters, and periods of homelessness. Though intermittently connected with outpatient care, his illness remained poorly controlled.<\/jats:p>","DOI":"10.1017\/s1092852925100394","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:59:47Z","timestamp":1752145187000},"source":"Crossref","is-referenced-by-count":1,"title":["Early intervention for schizophrenia: a pathway to improved clinical outcomes"],"prefix":"10.1017","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-3136","authenticated-orcid":false,"given":"Takesha","family":"Cooper","sequence":"first","affiliation":[{"name":"University of Nevada, Reno School of Medicine, Renown Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"S1092852925100394_r8","first-page":"485","article-title":"The \u201cclose-in\u201d or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder","volume":"28","author":"McGorry","year":"2002","journal-title":"Schizophr Bull."},{"key":"S1092852925100394_r7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15050632"},{"key":"S1092852925100394_r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.09.018"},{"key":"S1092852925100394_r11","unstructured":"11. US Food and Drug Administration. Clozaril [prescribing information]. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019758s062lbl.pdf."},{"key":"S1092852925100394_r1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2008.tb00182.x"},{"key":"S1092852925100394_r4","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.127753"},{"key":"S1092852925100394_r3","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.975"},{"key":"S1092852925100394_r13","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00243-1"},{"key":"S1092852925100394_r14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.7.903"},{"key":"S1092852925100394_r5","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000297663"},{"key":"S1092852925100394_r15","doi-asserted-by":"publisher","DOI":"10.1037\/0003-066X.59.7.614"},{"key":"S1092852925100394_r2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"S1092852925100394_r10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60486-9"},{"key":"S1092852925100394_r9","first-page":"CD007906","article-title":"Intensive case management for severe mental illness","volume":"1","author":"Dieterich","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"S1092852925100394_r6","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231158891"},{"key":"S1092852925100394_r12","unstructured":"12. US Food and Drug Administration. Frequently asked questions about the Clozapine REMS modification; 2024. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-andproviders\/frequently-asked-questions-clozapine-rems-modification. Accessed April 30, 2025."},{"key":"S1092852925100394_r17","first-page":"567","article-title":"Racial and ethnic disparities in first-episode psychosis: a review of the literature","volume":"72","author":"Oluwoye","year":"2021","journal-title":"Psychiatr Serv."}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852925100394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:39:13Z","timestamp":1759851553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852925100394\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"alternative-id":["S1092852925100394"],"URL":"https:\/\/doi.org\/10.1017\/s1092852925100394","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e69"}}